0.2000 -0.00 (-1.43%)
After hours: 5:55PM EDT
|Bid||0.2048 x 800|
|Ask||0.2089 x 900|
|Day's Range||0.1900 - 0.2100|
|52 Week Range||0.1500 - 1.4000|
|Beta (3Y Monthly)||1.44|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 8, 2018 - May 14, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.58|
Entering Phase 2 clinical trials for the treatment of Lymphatic Malformations which include a number of rare and orphan diseases. PHILADELPHIA, July 15, 2019 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX, "Aevi") today announced it has entered into an exclusive license agreement with OSI Pharmaceuticals, LLC, an indirect wholly-owned subsidiary of Astellas Pharma Inc. ("Astellas") for the worldwide development and commercialization of Astellas' second generation mTORC1/2 inhibitor, ASP7486 (OSI-027). Aevi's initial focus of study with ASP7486 will be for congenital Lymphatic Malformations, which includes a number of rare and orphan diseases.
CORAL GABLES, FL / ACCESSWIRE / March 12, 2019 / The healthcare stock market is comprised of innovative companies working diligently to design, manufacture, and commercialize state-of-the-art tech-driven solutions for the healthcare industry. It is the responsibility of healthcare companies to meet the oncoming challenges presented by infectious diseases and ailments, and so long as they can meet these requirements, the healthcare sector could generate market excitement. Premier Health Group (OTC:PHGRF) (CSE:PHGI), ENDRA Life Sciences Inc (NDRA), Novavax Inc (NVAX), and Aevi Genomic Medicine Inc (GNMX) are 4 healthcare companies raising the bar on Tuesday.
NEW YORK, Feb. 12, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
On January 2nd Aevi (GNMX) announced that ASCEND, the phase II trial evaluating their non-stimulant glutamatergic neuromodulator in pediatric and adolescent subjects with ADHD, failed to meet its primary endpoint of a statistically significant reduction of ADHD-RS at 6 weeks in either Part A (mGluR+ subjects) or Part B (mutation free subjects). As we have consistently stated in our coverage, given the largely positive results of SAGA and enrichment of ASCEND with only patients with mutations to nine select genes in the mGluR network, along with a pediatric weighting, we had expected ASCEND would prove successful. As a reminder about SAGA’s results (see link to our report), it did meet statistical significance on the CGI-I secondary endpoint as well as on the ADHD-RS responder measure (prespecified as decrease of ADHD-RS score of 30% or more, which is considered a clinical response).
HENDERSON, NV / ACCESSWIRE / January 8, 2019 / Celgene's major deal with Bristol-Myers Squibb seems to have woken up the sleeping giant that is the biotech market. Axsome announced positive trial data ...
Bristol-Myers Squibb Co (NYSE: BMY) announced a deal to buy Celgene Corporation (NASDAQ: CELG) in a cash and stock transaction with an equity value of approximately $74 billion. Separately, the company announced FDA approval for an expanded indication for its Sprycel tablets to include the treatment of pediatric patients one year of age and older, with newly diagnosed Philadelphia chromosome-positive, or Ph+, acute lymphoblastic leukemia in combination with chemotherapy.
PHILADELPHIA, Jan. 2, 2019 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (GNMX) ("the Company") today announced that the ASCEND trial, a genomically-guided Phase 2 double-blind, placebo-controlled clinical trial of orally-administered AEVI-001 (100 – 400 mg BID) in children aged 6 – 17 with Attention Deficit Hyperactivity Disorder (ADHD) with an mGluR copy number variant (Part A) or without an mGluR copy number variant (Part B), did not achieve statistical significance on the primary endpoint of reduction of ADHD-RS in either Part A or Part B after 6 weeks of treatment with AEVI-001. AEVI-001 was safe and well tolerated. Reported adverse events were minimal and similar across both Part A and Part B treatment groups.
CORAL GABLES, FL / ACCESSWIRE / December 20, 2018 / The healthcare industry is complicated, this much is certain, but amidst the complexities exist innovative approaches to healthcare that will ultimately provide the best quality of care for patients in the future. From advancements in the nascent telehealth industry to improved treatment options for patients, the healthcare sector may offer significant opportunities in the near future. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Aevi Genomic Medicine, Inc (GNMX), Aurinia Pharmaceuticals, Inc (AUPH), and CV Sciences, Inc (CVSI) are 4 pharma stocks to pay attention to heading into the rest of the week.
PHILADELPHIA, Nov. 26, 2018 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (GNMX) (the Company) announced today that the Aevi Genomic Medicine Management team will host a breakfast with Key Opinion Leader (KOL) Robert Findling, M.D., Leonard and Helen R. Stulman Professor in Child and Adolescent Psychiatry at Johns Hopkins University. During the breakfast they will discuss the diagnosis and treatment paradigms in Attention Deficit Hyperactivity Disorder (ADHD). The breakfast is being held on Thursday, November 29, 2019 at 8:00 AM EST at the National in New York, New York. Aevi Genomic Medicine, Inc. is dedicated to unlocking the potential of genomic medicine to translate genetic discoveries into novel therapies. Driven by a commitment to patients with pediatric onset life-altering diseases, the Company's research and development efforts leverage an internal genomics platform and an ongoing collaboration with the Center for Applied Genomics (CAG) at The Children's Hospital of Philadelphia (CHOP).
NEW YORK, Nov. 08, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Aevi Genomic Medicine (GNMX) reported Q3 financial results and provided a business update. Just two months later, GNMX announced that part ‘B’ (i.e. Also noteworthy is that while the initial plan was for parts A and B to enroll and read-out sequentially, given the rapid enrollment of part B, the expectation is now that top-line data will be announced for both in January.
On a per-share basis, the Wayne, Pennsylvania-based company said it had a loss of 12 cents. The company's shares closed at $1.09. A year ago, they were trading at $1.66. _____ This story was generated ...
PHILADELPHIA , Nov. 1, 2018 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the "Company") announced today financial and operational results for the three months ended September ...
PHILADELPHIA, Oct. 15, 2018 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (GNMX) (the Company) today announced that it has reached full enrollment of Part B of its Phase 2 ASCEND clinical trial. The ASCEND trial is a genomically-guided study in pediatric and adolescent patients with Attention Deficit Hyperactivity Disorder (ADHD) assessing the safety and efficacy of AEVI-001, a novel, non-stimulant therapy. Part B of the ASCEND trial is studying pediatric and adolescent patients with ADHD without mGluR mutations.
PHILADELPHIA , Aug. 29, 2018 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that Michael F. Cola , President and Chief Executive Officer, will present at the H.C. ...
PHILADELPHIA, Aug. 21, 2018 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (GNMX) (the Company) today announced the sale of 5.1 million shares of its common stock for aggregate proceeds of $4.9 million, before expenses. The sales were through the Company's existing ATM program, for which JMP Securities LLC acts as the Company's sales agent. The Company recently announced the completion of enrollment in Part A of the ASCEND trial and intends to use the net proceeds raised from the ATM to accelerate Part B of the ASCEND trial.
"We are pleased that we have completed enrollment in Part A of our ASCEND trial" said Garry A. Neil, M.D., Chief Scientific Officer of Aevi Genomic Medicine. ASCEND is an adaptive, 6-week, double-blind parallel-group study in children and adolescents (ages 6-17 years) with ADHD with and without copy number variants (CNVs) in specific genes implicated in glutamatergic signaling and neuronal connectivity.
Despite the slight additional delay to ASCEND (as a result of the optioned increased enrollment), we continue to think there may be several pipeline-related events over the very near term that could potentially favorably influence equity valuation and related pricing of any near-term financings. GNMX hopes to swap out AEVI-001 (which is in phase 2 mGlur+ ADHD ASCEND study) with an improved version. AEVI-004 provides the benefits of intellectual property protection (out to 2039) and is designed to maintain substantially similar solubility, dissolution and pharmakokinetics of AEVI-001 but with (per GNMX's press release) "greater stability and a higher melting point".
On a per-share basis, the Wayne, Pennsylvania-based company said it had a loss of 14 cents. The company's shares closed at $1.10. A year ago, they were trading at $1.20. _____ This story was generated ...
PHILADELPHIA , Aug. 2, 2018 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the "Company") announced today financial and operational results for the three months ended June 30 , ...
-FDA provisionally agreed that AEVI-004 is a co-crystal and a novel drug substance -FDA provisionally agreed existing AEVI-001 toxicology and pathology studies are acceptable to support clinical development ...